COMPANY PROFILE

Viestar

A new type of endoscopic microscopic imaging system, which adopts advanced biological cytology analysis technology principle, combined with exquisite optical system and unique algorithm processing…

Wuhan, ChinaFounded 2014Biotech & Life Sciences

Valuation $50–100M Last recorded · 2025

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Viestar

Biopsee.cn specializes in ultra high resolution in vivo microscopic imaging, providing advanced diagnostic solutions for the medical industry. The company serves healthcare providers, research institutions, and clinical laboratories, operating primarily in the medical imaging market. Biopsee.cn's business model revolves around the development and sale of cutting-edge imaging technology, which enables precise and detailed visualization of biological tissues in real-time. Revenue is generated through the sale of imaging devices, maintenance services, and software solutions that enhance diagnostic capabilities. The company aims to improve clinical outcomes by offering superior imaging quality that aids in early and accurate diagnosis.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: Wuhan, China
Employees: 5
Open positions: None listed
Dealroom signal: 24.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Nov 2025	$14M	$55M	Efung Capital	↗
SERIES B✓Equity / VC	Jul 2024	$2.8M	$11M	Tongxi Capital · SND Ventures Group · Kaixuan Capital	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Viestar website traffic

Latest recorded traffic for Viestar is 28K monthly website visits, up 64.7% over the last three months. Viestar's team grew 0% over the past year.

Latest monthly visits28K 3-month web change+64.7% 1-year team growth0%

Monthly website visitsOct 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SASansanimaHuman cell-based assays replacing animal testing.	Sheffield, United Kingdom	Operational	5	$396K	$1.6M
GAGametoA new breed of biotechnology company focused on understanding and eliminating infertility and menopause	New York City, United States	Operational
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
MTMuvon TherapeuticsMuvon Therapeutics is creating an autologous cell therapy for damaged skeletal muscles in SUI patients, with a primary focus on developing a safe treatment for stress urinary incontinence in women	Zurich, Switzerland	Operational
MBMyricx BioNovel antibody-drug conjugate payloads for cancer treatment	London, United Kingdom	Acquired
ADAdaptateDeveloping therapeutic antibodies to modulate gamma delta T cell activity for innovative immunotherapy solutions	London, United Kingdom	Acquired
VBViaNautis BioPolymer nanoparticle platform for targeted intracellular genetic delivery	Cambridge, United Kingdom	Operational
KTKeapstone TherapeuticsSmall molecule activators for neurodegenerative disease therapies	Sheffield, United Kingdom	Operational